Tag: Liver fibrosis

The FDA granted Rezdiffra accelerated approval in March 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. As MASH is a chronic condition, the question of how long do you take Rezdiffra is central for patients beginning this important long-term therapy. This article explores the factors influencing the duration of treatment.

According to the [FDA](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash), approximately 6% of U.S. adults are affected by MASH, a serious liver disease that can lead to scarring (fibrosis). Recently, major advances have answered the question: **What is the new medication for liver scarring?** by bringing the first-ever medications specifically for this condition to market, offering new hope for treatment.

According to the drug manufacturer, Rezdiffra is typically a long-term treatment intended for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The answer to **how long do you have to take Rezdiffra** is not a fixed timeline but is a personalized decision made in consultation with a liver specialist based on individual response.

With approximately 25-30% of the U.S. population affected by metabolic dysfunction-associated steatotic liver disease (MASLD), the recent FDA approval of the first medication to address this condition marks a significant breakthrough. Rezdiffra (resmetirom) is the new drug to reverse fatty liver damage, specifically targeting the more severe form known as MASH.

In mice studies, while crude *Coleus forskohlii* extract has been shown to induce fatty liver and hepatotoxicity, the isolated compound forskolin was not responsible for these adverse effects, highlighting a critical distinction for liver health.

The World Health Organization estimated that 254 million people were living with chronic hepatitis B (HBV) in 2022, a condition that can lead to severe liver damage [1.6.2]. A key question for patients is: **can tenofovir reverse liver damage** caused by this virus?

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. What is Rezdiffra, and how does this groundbreaking medication target liver damage to potentially reverse disease progression?

The human liver has a unique and remarkable capacity to regenerate after injury [1.4.2]. While no single drug can completely regenerate a damaged liver on its own, recent pharmacological advancements are showing significant promise in halting and even reversing liver damage [1.2.3, 1.2.4]. This article explores the question: What drug regenerates the liver?

In 2024, the U.S. Food and Drug Administration (FDA) approved the first-ever drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver disease. A **MASH drug** is a medication specifically designed to treat this condition, which is characterized by fat buildup, inflammation, and scarring in the liver. The approval of these specialized treatments marks a significant advancement for millions affected by this progressive disease, who previously had limited therapeutic options.

Affecting up to 38% of the global population, Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing concern [1.4.2]. This raises a critical question for many: **Can statins reverse fatty liver?** This article examines the evidence.